The Administrative Core (Core A) has the following specific aims: (1) to provide scientific leadership and coordination of the Program Project activities, assuring achievement of our scientific goals while maximizing scientific collaboration;(2) to promote productive communication among the Investigators and staff in the Projects and Cores, between Project Leaders, External Scientific Advisors, Program Officers, and other NIAID staff members;and (3) to provide fiscal oversight, administrative support, and ensure regulatory and grant policy compliance. The Administrative Core will be led by the Principal Investigator, Dr. Leonidas Stamatatos, who will manage, oversee and coordinate the efforts of each participant in the Program Project, with the assistance of the Project Manager. A group of external Scientific advisors will be formed to oversee the scientific activities of the HIVRAD Program Project and provide advice and support. This Core will oversee all aspects of this HIVRAD Program Project including scientific issues, regulatory affairs, finance, communication, coordination and administration of each of the Cores and Projects. This Core will ensure that expenditures and projections are commensurate with the goals of the overall project;monitor the fiscal and functional aspects of all subcontracts;and coordinate with the Grants and Contracts Offices at participating Institutions for the disbursement, expenditure and accounting of grant funds. It will facilitate communication among Project and Core leaders, the external Scientific Advisory Board and the NIAID Program Officer overseeing this Program Project and it will coordinate the preparation and submission of annual scientific and financial reports and renewal applications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI094419-03
Application #
8463119
Study Section
Special Emphasis Panel (ZAI1-BP-A)
Project Start
2013-05-01
Project End
2016-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
3
Fiscal Year
2013
Total Cost
$133,848
Indirect Cost
$32,025
Name
Seattle Biomedical Research Institute
Department
Type
DUNS #
070967955
City
Seattle
State
WA
Country
United States
Zip Code
98109
McGuire, Andrew T; Gray, Matthew D; Dosenovic, Pia et al. (2016) Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun 7:10618
Jardine, Joseph G; Kulp, Daniel W; Havenar-Daughton, Colin et al. (2016) HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351:1458-63
Tian, Ming; Cheng, Cheng; Chen, Xuejun et al. (2016) Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell 166:1471-1484.e18
Strong, Roland K; Finton, Kathryn A K (2016) The Broadly Neutralizing, Anti-HIV Antibody 4E10: an Open and Shut Case? J Virol 90:3274-5
Jardine, Joseph G; Ota, Takayuki; Sok, Devin et al. (2015) HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349:156-61
Zhou, Tongqing; Lynch, Rebecca M; Chen, Lei et al. (2015) Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell 161:1280-92
Dosenovic, Pia; von Boehmer, Lotta; Escolano, Amelia et al. (2015) Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell 161:1505-15
McGuire, Andrew T; Glenn, Jolene A; Lippy, Adriana et al. (2014) Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol 88:2645-57
McGuire, Andrew T; Dreyer, Anita M; Carbonetti, Sara et al. (2014) HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 346:1380-3
Finton, Kathryn A K; Friend, Della; Jaffe, James et al. (2014) Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10. PLoS Pathog 10:e1004403

Showing the most recent 10 out of 18 publications